Anti-IL-5 Treatment Reduces Deposition of ECM Proteins in the Bronchial Subepithelial Basement Membrane of Mild Atopic Asthmatics

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2003 Oct 3

PMID 14523040

Citations 259

Authors

Patrick Flood-Page

Andrew Menzies-Gow

Simon Phipps

Sun Ying

Arun Wangoo

Mara S Ludwig

Neil Barnes

Douglas Robinson

A Barry Kay

Affiliations

Soon will be listed here.

Abstract

Eosinophil-derived TGF-beta has been implicated in remodeling events in asthma. We hypothesized that reduction of bronchial mucosal eosinophils with anti-IL-5 would reduce markers of airway remodeling. Bronchial biopsies were obtained before and after three infusions of a humanized, anti-IL-5 monoclonal antibody (mepolizumab) in 24 atopic asthmatics in a randomized, double-blind, placebo-controlled study. The thickness and density of tenascin, lumican, and procollagen III in the reticular basement membrane (RBM) were quantified immunohistochemically by confocal microscopy. Expression of TGF-beta1 mRNA by airway eosinophils was assessed by in situ hybridization, and TGF-beta1 protein was measured in bronchoalveolar lavage (BAL) fluid by ELISA. At baseline, airway eosinophil infiltration and ECM protein deposition was increased in the RBM of asthmatics compared with nonasthmatic controls. Treating asthmatics with anti-IL-5 antibody, which specifically decreased airway eosinophil numbers, significantly reduced the expression of tenascin, lumican, and procollagen III in the bronchial mucosal RBM when compared with placebo. In addition, anti-IL-5 treatment was associated with a significant reduction in the numbers and percentage of airway eosinophils expressing mRNA for TGF-beta1 and the concentration of TGF-beta1 in BAL fluid. Therefore eosinophils may contribute to tissue remodeling processes in asthma by regulating the deposition of ECM proteins.

Citing Articles

Clinical Evidence of the Use of Mepolizumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Prospective Observational Study.

Moffa A, Iafrati F, Giorgi L, Nardelli D, Carnuccio L, Baptista P Healthcare (Basel). 2025; 13(4).

PMID: 39997294 PMC: 11855528. DOI: 10.3390/healthcare13040419.

Role of the TGF-β cytokine and its gene polymorphisms in asthma etiopathogenesis.

Plichta J, Panek M Front Allergy. 2025; 6:1529071.

PMID: 39949968 PMC: 11821632. DOI: 10.3389/falgy.2025.1529071.

Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment.

Gonzalez-Barcala F, Bobolea I, Dominguez-Ortega J, Banas-Conejero D, Antelo-Cea E, Martinez-Moragon E ERJ Open Res. 2025; 11(1).

PMID: 39902267 PMC: 11788806. DOI: 10.1183/23120541.00211-2024.

Epithelial-Mesenchymal Transition in Chronic Rhinosinusitis.

Choi T, Ryu S, Bae J, Yoo S, Mo J J Rhinol. 2024; 31(2):67-77.

PMID: 39664411 PMC: 11566545. DOI: 10.18787/jr.2024.00022.

Dual therapy with corticosteroid ablates the beneficial effect of DP2 antagonism in chronic experimental asthma.

Ullah M, Rittchen S, Li J, Curren B, Namubiru P, Ahmed T Nat Commun. 2024; 15(1):10253.

PMID: 39592603 PMC: 11599388. DOI: 10.1038/s41467-024-54670-8.

References

Wilson J, Li X . The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin Exp Allergy. 1997; 27(4):363-71. View

Hakonarson H, Maskeri N, Carter C, Chuang S, Grunstein M . Autocrine interaction between IL-5 and IL-1beta mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. J Clin Invest. 1999; 104(5):657-67. PMC: 408541. DOI: 10.1172/JCI7137. View

Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A . Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med. 1997; 155(6):1864-71. DOI: 10.1164/ajrccm.155.6.9196087. View

Li X, Wilson J . Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med. 1997; 156(1):229-33. DOI: 10.1164/ajrccm.156.1.9607066. View

Ying S, Meng Q, Zeibecoglou K, Robinson D, Macfarlane A, Humbert M . Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol. 1999; 163(11):6321-9. View

Zhang H, Phan S . Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol. 1999; 21(6):658-65. DOI: 10.1165/ajrcmb.21.6.3720. View

Paakko P, Kaarteenaho-Wiik R, Pollanen R, Soini Y . Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia. Am J Respir Crit Care Med. 2000; 161(3 Pt 1):967-72. DOI: 10.1164/ajrccm.161.3.9809115. View

Bousquet J, Jeffery P, Busse W, Johnson M, Vignola A . Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161(5):1720-45. DOI: 10.1164/ajrccm.161.5.9903102. View

Blyth D, Wharton T, Pedrick M, Savage T, Sanjar S . Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody. Am J Respir Cell Mol Biol. 2000; 23(2):241-6. DOI: 10.1165/ajrcmb.23.2.3999. View

10.

Leckie M, Ten Brinke A, Khan J, Diamant Z, OConnor B, Walls C . Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2001; 356(9248):2144-8. DOI: 10.1016/s0140-6736(00)03496-6. View

11.

Hoshino M, Takahashi M, Aoike N . Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001; 107(2):295-301. DOI: 10.1067/mai.2001.111928. View

12.

Ordonez C, Khashayar R, Wong H, Ferrando R, Wu R, Hyde D . Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med. 2001; 163(2):517-23. DOI: 10.1164/ajrccm.163.2.2004039. View

13.

Murphy-Ullrich J . The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J Clin Invest. 2001; 107(7):785-90. PMC: 199582. DOI: 10.1172/JCI12609. View

14.

Foster P, Mould A, Yang M, Mackenzie J, Mattes J, Hogan S . Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev. 2001; 179:173-81. DOI: 10.1034/j.1600-065x.2001.790117.x. View

15.

Trifilieff A, Fujitani Y, Coyle A, Kopf M, Bertrand C . IL-5 deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation. Clin Exp Allergy. 2001; 31(6):934-42. DOI: 10.1046/j.1365-2222.2001.01084.x. View

16.

Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D . Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002; 57(4):309-16. PMC: 1746305. DOI: 10.1136/thorax.57.4.309. View

17.

Schmid-Grendelmeier P, Altznauer F, Fischer B, Bizer C, Straumann A, Menz G . Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol. 2002; 169(2):1021-7. DOI: 10.4049/jimmunol.169.2.1021. View

18.

Phipps S, Ying S, Wangoo A, Ong Y, Levi-Schaffer F, Kay A . The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol. 2002; 169(8):4604-12. DOI: 10.4049/jimmunol.169.8.4604. View

19.

Liu L, Sedgwick J, Bates M, Vrtis R, Gern J, Kita H . Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol. 2002; 169(11):6459-66. DOI: 10.4049/jimmunol.169.11.6459. View

20.

Menzies-Gow A, Kay A, Robinson D . Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2002; 167(2):199-204. DOI: 10.1164/rccm.200208-789OC. View